Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Assessment of The Bethesda System for Reporting Thyroid Cytopathology
Lehrke, Heidi D., Zhang, Xiaotun, Badri, Osamah T Al, Rodríguez‐Gutiérrez, René , Delivanis, Danae A. , Ospina, Naykky Singh , Donegan, Diane , Hamidi, Oksana , Iñiguez‐Ariza, Nicole M. , Sharma, Anu , Kittah, Nana Esi, Tamhane, Shrikant , Andrade, Maria D Hurtado, Kotwal, Anupam , Jenkins, Sarah M. , Spears, Grant M. , Rivera, Michael , Dean, Diana S., Henry, Michael , Sauter, Jennifer L, Lehrke, Heidi, Al Badri, Osamah T, Rodríguez-Gutiérrez, René , Singh Ospina, Naykky, Iñiguez-Ariza, Nicole, Kittah, Nana Esi N, Tamhane, Shrikant U, Hurtado Andrade, Maria D, Spears, Grant, Henry, Michael R, Kudva, Yogish C , Hamidi, Oksana , Singh Ospina, Naykky , Sauter, Jennifer L. , Andrade, Maria D Hurtado, Albadri, Sam

Mayo Clinic

American Journal of Clinical Pathology | May 14, 2019 | Volume: 152 | Issue: 4 | Pages: 502-511

10.1093/ajcp/aqz076 | PMID 31305880 Get It

AbstractObjectivesLong-term follow-up is important for determining performance characteristics of thyroid fine-needle aspiration (FNA).MethodsHistologic or 3 or more years of clinical follow-up was used to calculate performance characteristics of thyroid FNA before and after implementation of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) classification was also investigated.ResultsFollow-up was obtained for 1,277/1,134 and 1,616/1,393 aspirates/patients (median clinical follow-up, 9.9 and 4.4 years, pre- and post-TBSRTC, respectively). Nondiagnostic, suspicious for follicular neoplasm, and suspicious for malignancy (SFM) diagnoses decreased and benign diagnoses increased post-TBSRTC, while atypical rate remained less than 1%. Negative predictive value for benign nodules and positive predictive value (PPV) for SFM increased significantly. Eleven nodules were reclassified as NIFTP, slightly decreasing PPV/risk of malignancy (ROM).ConclusionsAppropriate ROM for thyroid FNA can be achieved through application of TBSRTC terminology with minimal use of atypical category.
Soft tissue sarcoma stiffness and perfusion evaluation by MRE and DCE-MRI for radiation therapy response assessment: a technical feasibility study
Pepin, Kay , Grimm, Roger C., Howe, B. Matthew, Fritchie, Karen , Frick, Matthew A., Wenger, Doris E. , Okuno, Scott H. , McGee, Kiaran P. , James, Sarah, Laack, Nadia N., Herman, Michael , Pafundi, Deanna, Grimm, Roger, Kargar, Soudabeh , Frick, Matthew, Wenger, Doris, Ehman, Richard, McGee, Kiaran , Ehman, Richard L.

Mayo Clinic

Biomedical Physics & Engineering Express | May 13, 2019 | Volume: 5 | Issue: 4 | Pages: 047003

10.1088/2057-1976/ab2175 | PMID 32110433 Get It

Abstract Soft tissue sarcomas are a rare and heterogeneous group of malignancies that present significant diagnostic and therapeutic challenges. Patient stratification based on tumor aggressiveness and early therapeutic response based on quantitative imaging may improve prediction of treatment response and the evaluation of new treatment strategies in clinical trials. The purpose of this pilot study was to determine the technical feasibility of magnetic resonance elastography (MRE) and dynamic contrast-enhanced (DCE) MRI for the evaluation of sarcoma stiffness and perfusion in 9 patients with histologically confirmed sarcoma. Additionally, we assessed the feasibility of utilizing MRE and DCE-MRI for the early evaluation of response to radiation therapy in 4 patients to determine the utility of further evaluation in a larger cohort study. Tumor size, stiffness, and perfusion parameters all decreased from baseline at the time of the pre-surgery or follow-up MRI, and results were compared to pathology or conventional imaging. MRE and DCE-MRI may be useful for the quantitative evaluation of tumor stiffness and perfusion, and therapy response assessment in soft tissue sarcomas.
Abstract PD2-01: Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL
Magbanua, MJM, Hirst, GL, Wolf, DM, Ma, AA, Bergin, Emily, Venters, Sara J., Salari, Raheleh, Tin, T., Sawyer, Sarah , Louie, MC, Zimmermann, B, Lin, C-HJ, Liang, WS, Cuyugan, Lori, Chien, AJ, Forero, Andres , Liu, M, Delson, AL, Asare, Smita , Esserman, L., Veer, Laura van’t, Hirst, Gillian L. , Hirst, Gillian L , Swigart, Lamorna Brown , Yau, Christina , Sethi, Himanshu , Wu, Hue-Tsi , Keats, Jonathan J. , Enriquez, D, Tripathy, Debu , DeMichele, Angela

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: PD2-01-PD2-01

10.1158/1538-7445.sabcs18-pd2-01 Get It

Abstract ctDNA analysis offers a non-invasive approach for monitoring response and resistance to treatment. Serial ctDNA testing during neoadjuvant therapy (NAT) may provide early indicators of emerging resistance and disease progression. In this study, we analyzed ctDNA from high-risk early breast cancer patients who received NAT and definitive surgery in the I-SPY 2 TRIAL (NCT01042379). We hypothesize that (1) assessment of ctDNA levels early in treatment will improve the performance of molecular and imaging-based predictors of pathologic complete response (pCR) to NAT; and (2) levels of ctDNA after NAT are associated with residual cancer burden and recurrence [distant recurrence free survival (DRFS)]. Methods: ctDNA analysis was performed in 84 high-risk stage II and III breast cancer patients randomized to neoadjuvant investigational agent (n=52), AKT inhibitor MK-2206 (M) in combination with paclitaxel (T) followed by doxorubicin and cyclophosphamide (AC) (M+T->AC), or standard-of-care (T->AC) (n=32). HER2+ patients also received trastuzumab (H). Serial plasma was collected before NAT (T0), early treatment (3 weeks, T1), between regimens (12 weeks, T2), and after NAT prior to surgery (T3). Mutational profiles derived from pretreatment tumor biopsy and normal matched DNA whole exome sequencing were used to design personalized assays targeting 16 patient-specific somatic variants to detect ctDNA in serial plasma. Results: Of the 84 patients in this study, 43% were HR-/HER2- (TNBC), 35% HR+/HER2-, and 23% HER2+. In total, 74% (61 of 83), 35% (28 of 79), 14% (9 of 65), and 8% (5 of 61) were positive for ctDNA at timepoints T0, T1, T2, and T3, respectively. At T0, ctDNA positivity and levels (average number of mutant molecules detected per mL) were significantly associated with increased tumor burden (by clinical and MRI examination), more aggressive tumor biology (as reflected in higher Mammaprint scores and grade) and subtype (HER2+ and TNBC). Twenty-seven percent (27%) of the 84 patients achieved a pCR and all patients who were ctDNA-positive at T3 (n=5) did not achieve a pCR. Currently, data are being collected to: (1) assess the relationship of ctDNA and MRI imaging in predicting tumor response to therapy; (2) examine the relationship of ctDNA levels before and after NAT with 3-year DRFS and event-free survival (EFS). The results of these analyses will be presented at the SABCS 2018 meeting. Conclusions: Our study provides a platform to evaluate the clinical significance of ctDNA for serial monitoring of response to NAT. Accurate and early response prediction by highly sensitive ctDNA analysis can facilitate a timely and judicious change in treatment to improve patients' chances of achieving a pCR. Finally, personalized ctDNA testing may complement imaging and pathologic evaluation of tumor response to fine-tune pCR as a surrogate endpoint for improved DRFS and EFS. Citation Format: Magbanua MJM, Brown-Swigart L, Hirst GL, Yau C, Wolf D, Ma AA, Bergin E, Venters S, Sethi H, Wu H-T, Salari R, Tin T, Sawyer S, Louie M, Zimmermann B, Lin C-HJ, Keats J, Liang WS, Cuyugan L, Enriquez D, Tripathy D, Chien AJ, Forero A, DeMichele A, Liu M, Delson AL, Asare S, Esserman L, van't Veer L, I-SPY 2 Consortium. Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD2-01.
Abstract OT3-03-01: Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer
Isakoff, SJ, Jelovac, Danijela, Liem, André , Liu, MC, Milillo, Adriana, Nangia, Julie R. , Page, David B. , Reeves, J. N. , Santa‐Maria, Cesar A. , Duncan, Mark D. , Graham, J., Chen, J , Dezube, BJ, Han, Hyo S , Hamilton, Erika , Irie, Hanna Y. , Liem, A, Reeves, J, Santa-Maria, C, Duncan, M, Graham, JR, Dezube, B. J., Spring, Laura

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: OT3-03-01-OT3-03-01

10.1158/1538-7445.sabcs18-ot3-03-01 Get It

Abstract Background: Neoadjuvant chemotherapy is administered to patients with operable breast cancer to downstage the tumor to allow for less extensive surgery and to provide prognostic information about drug efficacy and risk of disease recurrence. Patients who achieve a pathological complete response (pCR) following neoadjuvant treatment have a more favorable outcome than patients with residual invasive disease. Single-agent poly(ADP-ribose) polymerase (PARP) inhibitors have clinical efficacy in BRCA-mutated breast cancer. Niraparib, a potent and selective PARP1/2 inhibitor, is approved for maintenance treatment of patients with recurrent ovarian cancer and has demonstrated strong antitumor activity in in vivo studies with BRCA1-mutant breast cancer. The objective of this study is to evaluate the antitumor activity of single-agent niraparib in the neoadjuvant treatment of patients with localized, human epidermal growth factor receptor 2 (HER2)-negative, BRCAmut breast cancer. Trial Design: This is an open-label, single-arm pilot study with a target enrollment of 20 evaluable patients. Eligible patients are those ≥18 years old with histologically-confirmed HER2-negative localized breast cancer and either a BRCA1 or BRCA2 mutation (germline or somatic) and no prior anti-cancer therapies for the current malignancy. Patients will receive 200 mg of oral niraparib once daily for 2 months, after which they may either proceed directly to surgery or receive chemotherapy at the discretion of the physician. The primary endpoint is tumor response rate based on the change in tumor volume as measured by breast MRI after 2 months of treatment with niraparib; a response is defined as ≥30% reduction of tumor volume from baseline. Secondary endpoints include pCR rate, tumor response rate based on the change in tumor volume as measured by breast ultrasound, and safety and tolerability. Data will be summarized in a descriptive nature by frequency distributions (number and percentage of patients) for categorical variables and by the mean, median, and standard deviation for continuous variables. Tumor response rate will be tabulated together with its 95% binomial exact confidence interval. Funding: TESARO, Inc., Waltham, MA, USA sponsored the study. Citation Format: Han H, Hamilton E, Irie H, Isakoff S, Jelovac D, Liem A, Liu MC, Milillo A, Nangia J, Page D, Reeves J, Santa-Maria C, Duncan M, Graham JR, Chen J, Dezube BJ, Spring L. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-03-01.
Abstract ES11-2: Current status of diagnosis, monitoring, and non-surgical management of lymphedema
McLaughlin, Sarah A.

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: ES11-2-ES11-2

10.1158/1538-7445.sabcs18-es11-2 Get It

Abstract Lymphedema (LE) is a common but underreported complication of breast cancer treatment since most studies lack baseline and follow-up measurements or follow-up that is long enough to adequately record true incidence. Contemporary prospective randomized trials continue to document the occurrence of lymphedema after any axillary treatment and note that combination therapy with axillary surgery and radiation nearly doubles LE risk. Over the last 5 years clinicians have witnessed a paradigm shift in the diagnostic practices of LE with concerted efforts focusing on early detection as opposed to reactionary interventions. Controversy however has existed over how to define and diagnose LE and as such the literature surrounding diagnosis is heterogeneous with respect to incidence and recommendations. Existing guidelines emphasize the need for routine monitoring for LE and the critical importance of baseline, bilateral, and longitudinal limb assessments but do not embrace one measurement technique. A growing body of prospective observational data is systematically challenging the value of precautionary behaviors. Further, prospective randomized data demonstrates exercise does not promote the development of LE. Complex decongestive therapy remains the cornerstone of non-surgical LE treatment. With the NCI predicting over 4 million breast cancer survivors in the US by 2024, lymphedema is potentially a significant public health burden. Citation Format: McLaughlin S. Current status of diagnosis, monitoring, and non-surgical management of lymphedema [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr ES11-2.
Medial approach to the peroneal vessels as recipients for free flap reconstruction of the leg
Elswick, Sarah M. , Miglani, Amar , Lettieri, Salvatore C.

Mayo Clinic

Microsurgery | May 10, 2019 | Volume: 40 | Issue: 2 | Pages: 229-233

10.1002/micr.30462 | PMID 31074530 Get It

AbstractThe anatomic variation in the branching pattern of the popliteal vessel has been well‐established. Little has been written in the literature regarding recipient vessel selection for microvascular reconstruction in the lower extremity as it pertains to aberrant vascular anatomy. We present the case of a 57‐year‐old male patient who sustained a closed right lower extremity pilon fracture in a motor vehicle accident. The patient was initially treated with external fixation, which was followed by definitive open reduction and internal fixation 3 weeks later. Over the next 2 weeks, the patient developed skin ischemia of the anterior ankle. A free‐tissue transfer was planned. A digital subtraction angiogram revealed absence of the posterior tibial (PT) vessels and an aberrant course of the peroneal (PR) artery. In the operating room, the medial distal leg was explored for the PT vessels, which were severely hypoplastic. Given the close proximity of the PR vessels, the dissection was extended proximally to assess these vessels for microvascular anastomosis. They were found to be suitable. A parascapular flap was harvested and transferred to the right leg wound without any significant stretch on the vessels for soft tissue coverage. The flap demonstrated excellent inflow and outflow, and the leg and foot remained well perfused. The patient's postoperative course was uncomplicated. The technique of exposing the peroneal vessels for microvascular anastomosis via a medial approach is described. This technique is an excellent option to have available when aberrant anatomy precludes the use more commonly utilized vessels.
Abstract QS2: Influence of Race, Income, Insurance and Education in Rate of Breast Reconstruction: an NCDB 2004–15 Analysis
Restrepo, David J. , Huayllani, María T. , McLaughlin, Sarah A. , Rinker, Brian, Forte, Antonio J. , Forte, Antonio Jorge , Boczar, Daniel , Sisti, Andrea , Oliver, Jeremie D. , Gabriel, Emmanuel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 29, 2019 | Volume: 7 | Issue: 4S | Pages: 103-104

10.1097/01.gox.0000558422.58801.80 Get It

MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.
Burris, Howard A. , Hurwitz, Herbert I. , Perez, Edith A. , Hainsworth, John D. , Leon, Larry, Beattie, Mary, Brammer, Melissa, Spigel, David R. , Swanton, Charles , Leon, Larry, Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS11111-TPS11111

10.1200/jco.2015.33.15_suppl.tps11111 Get It

A phase I study of vemurafenib and decitabine in metastatic melanoma.
Engelman, Eric Steven, Leon‐Ferre, Roberto A. , Abushahin, Laith , Mott, Sarah C, Phadke, Sneha Deepak , Zakharia, Yousef , Milhem, Mohammed

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9056-9056

10.1200/jco.2015.33.15_suppl.9056 Get It